Do childhood vaccines have non-specific effects on mortality? a
William O. Cooper,1 Thomas G. Boyce,2 Peter F. Wright,3 & Marie R. Griffin4

Abstract A recent article by Kristensen et al. suggested that measles vaccine and bacille Calmette–Guérin (BCG) vaccine might reduce mortality beyond what is expected simply from protection against measles and tuberculosis. Previous reviews of the potential effects of childhood vaccines on mortality have not considered methodological features of reviewed studies. Methodological considerations play an especially important role in observational assessments, in which selection factors for vaccination may be difficult to ascertain. We reviewed 782 English language articles on vaccines and childhood mortality and found only a few whose design met the criteria for methodological rigor. The data reviewed suggest that measles vaccine delivers its promised reduction in mortality, but there is insufficient evidence to suggest a mortality benefit above that caused by its effect on measles disease and its sequelae. Our review of the available data in the literature reinforces how difficult answering these considerations has been and how important study design will be in determining the effect of specific vaccines on all-cause mortality.

Keywords Measles vaccine; Diphtheria-tetanus-pertussis vaccine/adverse effects; BCG vaccine; Infant mortality; Measles/mortality; Sudden infant death/etiology; Tuberculosis, Pulmonary/mortality; Review literature (source: MeSH, NLM).

Mots clés Vaccin antimorbillieux; Vaccin diphtérie-tétanos-coqueluche/effets indésirables; Vaccin BCG; Mortalité nourrisson; Rougeole/mortalité; Mort subite nourrisson/étologie; Tuberculose pulmonaire/mortalité; Revue de la littérature (source: MeSH, INSERM).

Palabras clave Vacuna antisarampión; Vacuna difteria-tétano-pertussis/efectos adversos; Vacuna BCG; Mortalidad infantil; Sarampión/mortalidad; Muerte súbita infantil/etología; Tuberculosis pulmonar/mortalidad; Literatura de revisión (fuente: DeCS, BIREME).

Introduction A recent article by Kristensen et al. (1) suggested that measles vaccine and bacille Calmette–Guérin (BCG) vaccine might reduce mortality beyond what is expected simply from protection against measles and tuberculosis. The authors argued that measles vaccine was associated with dramatic reductions in mortality in the absence of measles disease, and that the reductions in mortality were unlikely to be due to selection factors associated with vaccination because analysis of children vaccinated with diphtheria–tetanus–pertussis vaccine (DTP) showed the opposite effect — that is, mortality was higher in DTP-vaccinated children than in children who had not received DTP (1). The Kristensen study raised at least three important questions that have implications for public policy (2, 3). First, does the introduction of vaccines into populations result in disease-specific reductions in mortality other than those expected? Second, is the receipt of some vaccines associated with an increase in mortality? Third, which observational study designs can best answer the latter question by controlling for selection factors associated with receipt of vaccination? If some vaccines produce unexpected effects on mortality and some study designs are better able to address the above issues, there would be important implications for vaccine implementation and the planning of clinical trials and post-marketing surveillance.

We undertook a structured review that included considerations of study methodology to explore potential relationships between vaccines and childhood mortality (4–6).

Methods and Results
Identification of articles
We performed a structured review of articles describing childhood vaccines and mortality. Search, review, and selection criteria were developed before the initiation of the study. MEDLINE (1966 to March 2001), EMBASE (1980 to March 2001), and Current Contents were searched in March 2001. Studies of death were identified using the subject headings: “mortality”, “cause of death”, “sudden infant death”, “fatal outcome”, “death certificates”, and “death, sudden”. Studies of vaccine components were identified using the subject headings “diphtheria toxoid”, “diphtheria–tetanus–pertussis vaccine”, “tetanus toxoid”,

---

1 Associate Professor of Pediatrics, Vanderbilt Children’s Hospital Outpatient Center, Suite 5028 MCE, Nashville, TN 37232-8555, USA (email: william.cooper@Vanderbilt.Edu). Correspondence should be sent to this author.
2 Assistant Professor of Pediatrics, Mayo Clinic, Rochester, USA.
3 Professor of Pediatrics, Vanderbilt University Medical Center, Nashville, USA.
4 Professor of Preventive Medicine and Medicine, Vanderbilt University Medical Center, Nashville, USA.
Ref. No. 02-0406

* This work was presented at the WHO Measles Vaccine Steering Committee Meeting in Geneva on 29 April 2003.
“diphtheria-tetanus-pertussis vaccine”, “bacterial vaccines”, “bcg vaccine”, “measles vaccine”, “mumps vaccine”, “polio vaccine”, “polio vaccine, oral”, and “rubella vaccine”. Studies of deaths and studies of vaccines were then combined and limited to studies of infants or children, studies in humans, and studies written in English.

One of the authors (TGB) reviewed the abstract of each of the 782 articles identified using the above search strategy and excluded articles that did not include children, study the vaccines of interest, include a control group, or assess mortality. If information regarding exclusion criteria was not included in the abstract, or was unclear (n = 102), the full article was independently reviewed by two other authors (WOC, MRG). At this stage of our review, articles were excluded for the above reasons or if they described only condition-specific mortality (that is, from a single condition such as diarrhoea or cancer).

Assessment of methodological quality
All articles that met the screening criteria were then reviewed by two of the authors (WOC, MRG) using assessment of methodological issues developed a priori. Study design was incorporated into assessment of methodology to account for differences among cohort studies and case–control studies. Methodological criteria included: (1) completeness of mortality ascertainment (i.e. was there independent verification of death? Was cause of death determined by a health care practitioner?); (2) adequacy of follow-up (i.e. was there differential follow-up among study groups?); (3) consideration of sociodemographic differences between study populations (i.e. was any attempt made to control for living conditions, parental education, or family income?); (4) comparability of vaccinated and unvaccinated children and potential reasons for vaccination vs non-vaccination (i.e. were children who were unvaccinated different from vaccinated children with respect to socioeconomic status, use of health care, or overall health status?); and (5) absence of a strong co-intervention (i.e. did children in the study receive health-related interventions as a part of being in the study?) (4–6).

Selected articles
From the 782 studies identified in the original literature search, 753 were excluded (Fig. 1). We reviewed the remaining 29 articles and their reference lists, and from these we identified an additional six studies that met our review criteria. This gave us a total of 35 articles describing 24 separate observational studies. Twelve of these 24 studies compared differences in mortality among children receiving standard measles vaccine and unvaccinated children. Three of these 12 investigations attempted to focus on measles-specific mortality by counting only deaths following documented measles infection, but they are included here because of the difficulty in accurately assigning the cause of death to measles. The other nine measles vaccine studies compared all-cause mortality among vaccinated and unvaccinated children. Two of these studies also compared mortality among children with and without exposures to DTP, BCG, and polio vaccines. There were four studies of the risk of sudden infant death syndrome (SIDS) associated with DTP vaccine.

Measles vaccine and deaths following measles
Three studies enumerated both measles infections and deaths following measles infection among vaccinated and unvaccinated children (Table 1, web version only, available at: http://www.who.int/bulletin) (7–9). In the two studies from Kenya (7, 8), the incidence of measles was nearly 40% among unvaccinated children, whereas it was much lower in Ghana (3.6%) (9). Vaccinated children experienced 40–70% fewer cases of measles and 62–86% fewer deaths following measles. The absolute reduction of deaths was high in the Kenya studies (2.1% and 3.6%) and much lower in Ghana (4.9 per 1000 person years of follow-up). There was no enumeration of deaths among vaccinated and unvaccinated children who did not have symptomatic measles illness.

Measles vaccine and all-cause mortality
Nine studies evaluated all-cause mortality among vaccinated and unvaccinated children without regard to measles illness (Table 2, web version only, available at: http://www.who.int/bulletin) (1, 10–18). None of the nine studies was a randomized controlled trial. The age of the study children at the time of vaccination ranged from 6 to 13 months, except for one study (11, 12) in which children were vaccinated up to 60 months of age. Follow-up ranged from 4 to 54 months, with five of the studies following children until their fifth birthday (10–14, 17).

Two studies met all five criteria for high-quality observational studies as outlined above (10–12). In the Kasongo Project from Zaïre (10), 291 vaccinated children were compared with 345 unvaccinated children (Table 2, web version only, available at: http://www.who.int/bulletin). Mortality in the two groups was comparable at baseline and measles illness was present in the study area. Mortality was carefully ascertained and study children were followed to their fifth birthday. Children in the vaccinated group were vaccinated at a mean age of 8.8 months, with vaccination coverage reported to be 83%. There were no important differences in sociodemographics or health status between the two groups. In the study from Bangladesh (11, 12), 8135 vaccinated children were compared with 8135 unvaccinated children in the Matlab Field Study Area. Mortality was assessed through visits by health care workers every two weeks in the field area. Mortality was comparable at baseline among the two groups and measles disease was present in the study area. Children were followed to their fifth birthday and the mean age of vaccinated children was 9 months, with a vaccination coverage of 82%.

In these two studies that met all five criteria for study quality, there was a 31% reduction in mortality among children
in the vaccinated population in Zaire (10) and a 46% reduction in mortality among children in the vaccinated population in Bangladesh (11, 12) compared with childhood mortality in the selected unvaccinated populations. The absolute reductions in mortality — that is, the decreases in the overall expected mortality rate among the vaccinated cohorts — in the two studies were 2.1% and 1.8%, respectively.

The other seven studies all compared vaccinated and unvaccinated children in the same population and did not enumerate factors associated with health status that may have been associated with vaccination. The decreases in mortality in these studies tended to be greater (35% to 85%) than the two studies above and the absolute reductions in mortality (available for four of these studies) were 2.1–5.3% (Table 2, web version only, available at: http://www.who.int/bulletin). Although the study of Kristensen et al. (1) reported a reduction in mortality of 52%, which was similar to the other studies, the absolute reduction in mortality was extremely high given the short follow-up (4 months).

**DTP vaccine and SIDS**

Four studies, described in five papers, assessed the relationship between DTP vaccine and SIDS (Table 3) (19–23). These studies assessed 884 SIDS deaths among more than 350 000 children in England, France, and the USA. Three of these studies had adequate assessment of mortality and follow-up (19–21) but only one of them accounted for sociodemographic differences among study groups (19). None had strong co-interventions. In all four studies, vaccinated children were compared with unvaccinated children.

Reported relative reductions in SIDS mortality associated with DTP vaccine ranged from 30–80%, which were statistically significant in two of the four studies (19, 20). Notably, the large US study, which involved detailed maternal interviews and analyses that controlled for child and maternal factors, reported a statistically significant 30% decrease in the risk of SIDS associated with DTP immunization (19).

**Other vaccines and non-specific mortality**

Two of the studies from West Africa comparing mortality among those who did and did not receive measles vaccine (Table 1, web version only, available at: http://www.who.int/bulletin) also compared mortality among unvaccinated children and children receiving other vaccines (1, 18). Both of these studies had adequate assessment of mortality and adequate follow-up, although only one included sociodemographic factors (18). In the other study, there was a strong co-intervention present (1).

In the study from Benin West Africa (18), although the estimated increase in mortality following one dose of DTP and one dose of oral poliovirus vaccine (OPV) was elevated compared with unvaccinated children (relative risk = 2.2), this increase was not statistically significant. The risk estimate decreased with increasing numbers of DTP doses from 2.2 at one dose of DTP to 0.7 at four doses. With respect to BCG vaccine, the estimate for mortality reduction in vaccinated vs unvaccinated children was 0.38.

In the study from Guinea-Bissau (1), one dose of DTP (and OPV, which was almost always given with DTP) vaccine was associated with increased mortality. As in the Benin, West Africa study, the estimated increase in mortality associated with one dose of DTP and one dose of OPV was not statistically significant, although the risk estimate decreased with increasing numbers of DTP doses from 2.2 at one dose of DTP to 0.7 at four doses. With respect to BCG vaccine, the estimate for mortality reduction in vaccinated vs unvaccinated children was 0.38.

---

**Table 3. Studies assessing the relationship between DTPa vaccine and mortality due to SIDSb**

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Location</th>
<th>Years of study</th>
<th>No. of births</th>
<th>No. of SIDS cases</th>
<th>No. of controls</th>
<th>Complete ascertainment of mortality?</th>
<th>Adequate follow-up?</th>
<th>Consider sociodemographics?</th>
<th>Vaccinated and unvaccinated comparable?</th>
<th>Absence of strong co-intervention?</th>
<th>Relative reduction in mortality (%)c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoffman et al., 1987</td>
<td>Matched case–control</td>
<td>United States</td>
<td>1978–9</td>
<td>347 800</td>
<td>716</td>
<td>757</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>40</td>
</tr>
<tr>
<td>Walker et al., 1987</td>
<td>Matched case–control</td>
<td>United States</td>
<td>1972–83</td>
<td>26 500</td>
<td>29</td>
<td>262</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>80</td>
</tr>
<tr>
<td>Pollock et al., 1984</td>
<td>Cohort</td>
<td>England</td>
<td>1978–80</td>
<td>10 028</td>
<td>4</td>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>40</td>
</tr>
<tr>
<td>Bouvier-Colle et al., 1989; Flahaut et al., 1988</td>
<td>Matched case–control</td>
<td>France</td>
<td>1986</td>
<td>135</td>
<td>401</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>30</td>
<td>(-10 to 50)</td>
</tr>
</tbody>
</table>

a DTP = diphtheria and tetanus toxoids and pertussis vaccine.
b SIDS = sudden infant death syndrome.
c Numbers in parentheses are 95% confidence intervals.

---
Africa study, the estimate of mortality risk declined with increasing numbers of DTP vaccines received. For children who received BCG vaccine only, there was a significant reduction in mortality risk. Because children who weighed less than 2500 g did not receive BCG, there was a separate analysis for children aged 1 to 2 months who were either unvaccinated or vaccinated with BCG after the first month of life. Compared with children who remained unvaccinated, infants less than 6 months of age who were vaccinated with BCG after the first month of life experienced a significant reduction in mortality.

Comment

A recent study (1) suggested that in countries where childhood mortality is high, receipt of measles vaccine may confer benefits even in the absence of measles infections; however, higher mortality was suggested for children who were vaccinated with DTP and/or polio vaccines compared with those who were not (24). Our review of the English language literature of controlled observational studies of childhood vaccines and mortality yielded relatively few studies, and only two met all our methodological criteria (10–12). These criteria included: complete ascertainment of mortality, adequate follow-up, control for potential bias related to differences between vaccinated and unvaccinated children, and lack of a strong health-related co-intervention. Of note, no study directly addressed the key question of evidence of mortality differences among vaccinated and unvaccinated children in a population with concurrent morbidity and mortality surveillance in children who did not develop the target infection.

We considered the two studies from Zaire and Bangladesh (10–12) to be the strongest methodologically because they avoided the problem of selection bias associated with vaccine receipt; for example, vaccination may be strongly linked to other health practices. These two studies suggested that measles vaccine saved the lives of 2–3% of children in populations where disease was endemic, the vaccine was introduced, and uptake of vaccine was relatively high. These reductions were similar to those found in the studies reviewed here (7, 8) in which measles incidence was high and mortality was measured in defined periods following measles disease. These effects are also consistent with previous estimates of measles-associated mortality — that is, 2–4% mortality in the month following measles in countries where virtually all children contract measles and where childhood mortality is relatively high (25).

In several studies, strong mortality differences between vaccinated and unvaccinated children were observed in the absence of obvious measles-associated disease in the population. Measles-associated deaths may be particularly difficult to identify correctly; for example, in the malnourished or immunocompromized child a rash might not be present (26–28). Measles infection is also more severe among malnourished populations, and infection itself causes malnutrition and persistent growth delays (26–28). Because of these prolonged effects, infected children often experience prolonged increased mortality for 6 to 12 months following acute infection (27). Thus, it may be difficult to distinguish measles-associated deaths from “non-specific” mortality.

Most of the other studies reviewed suggested greater decreases in mortality associated with receipt of measles vaccine, often over shorter time periods, and in some cases as mentioned above, with no evidence of measles illness. This suggests that other baseline differences between vaccinated and unvaccinated children may have been responsible for at least some of the observed differences in death rates. This is a type of selection bias that has also plagued studies of DTP and SIDS.

Studies of DTP vaccine and SIDS reported a strong protective effect of vaccination, even in the large US study that included careful collection of and control for multiple maternal and infant characteristics that were potential confounding factors (19). A previous review of similar data by the United States Institute of Medicine (29) concluded that there were probably strong differences between vaccinated and unvaccinated children that were not easily identifiable. Because the differences between vaccinated and unvaccinated children were believed to be so important, and virtually impossible to identify and control for adequately, several investigators ultimately included only vaccinated children and examined the timing of SIDS in relation to DTP vaccine (29). These latter studies, which were considered methodologically stronger, showed no link between DTP vaccine and SIDS.

In studies of the effects of other vaccines on mortality, two studies suggested increased mortality in children who received DTP vaccine (1, 18). In both of these studies, mortality risk decreased with increasing numbers of DTP vaccine, suggesting that receipt of only one DTP vaccine (rather than all recommended doses) might be associated with poorer health status. BCG vaccination gave a level of protection from mortality. Because selection factors for receipt of BCG vaccine are significant, randomized controlled trials or, in their absence, observational designs that compare similar vaccinated and unvaccinated populations will be necessary to determine the true effect of BCG vaccine on overall mortality.

We were unable to perform formal meta-analysis on the included studies because study populations were heterogeneous, only two studies were considered to be methodologically strong, and the studies involved different age groups and different periods of follow-up.

Conclusions

In the absence of randomized controlled trials, innovative ways to assess the impact of vaccine programmes are warranted. First, clinical trials of vaccines should incorporate safety and mortality assessments in the design. Second, observational studies should attempt to identify and control for important differences between vaccinated and unvaccinated children that may contribute to childhood mortality. Third, post-marketing surveillance of vaccines in both the developed and the developing world are needed to detect unexpected adverse events as well as unexpected beneficial effects of vaccines on childhood mortality. Ongoing monitoring of child mortality is a key outcome, especially in areas of the world where childhood mortality is high. With the introduction of new vaccines a broad look at vaccine effectiveness against morbidity and mortality is warranted. For example, in the Gambia, Haemophilus influenzae vaccination showed an unpredicted protection against pneumonia in vaccine trials (30). The natural differences in the start-up time of new programmes in similar and adjacent geographical areas can provide an opportunity for such assessments (24).

Recommendations

Our review highlights the enormous impact of measles on childhood mortality and the tremendous contribution of measles
vaccine in reducing mortality. The provocative article by Kristensen (1) has raised questions that should be addressed using study designs that address some of the limitations identified in studies selected for our review. Time-series designs might be possible in studies that included large populations of children with careful measurement of mortality and a well-defined intervention point such as a mass immunization campaign. In situations where vaccine programmes are implemented over time due to cost or other constraints, comparison of mortality in carefully selected populations who receive vaccines in sequential order might be possible. Finally, in circumstances where a new vaccine is introduced or a new age at vaccination is being studied, randomized controlled trials with a large sample size would allow comparison of mortality among vaccinated and unvaccinated children. Whatever the study design, designs that avoid selection factors for vaccine should be used to further address these questions.

Acknowledgement
We would like to thank Patricia Erwin for assistance in conducting the literature searches.

Conflicts of interest: PFW receives support for clinical trials of experimental, new vaccines from Wyeth-Lederle Vaccines, Merck, and Aviron. MRG is paid by Merck to chair an endpoint committee for clinical trials on anti-inflammatory drugs and has received a non-restricted educational grant from Merck to study vaccine use in nursing homes.

Résumé
Les vaccins de l’enfance ont-ils des effets non spécifiques sur la mortalité ?
Un article récent de Kristensen et al. donne à penser que le vaccin antirougeoleux et le BCG (bacille Calmette-Guérin) pourrait entraîner une diminution de la mortalité qui dépasse ce que l’on peut attendre de la simple protection contre la rougeole et la tuberculose. Les études antérieures sur les effets potentiels des vaccins de l’enfance sur la mortalité n’ont pas tenu compte des caractéristiques méthodologiques. Or celles-ci revêtent une importance particulière dans les évaluations résultant d’observations, pour lesquelles il peut être difficile d’objectiver les facteurs de sélection pour la vaccination. Nous avons passé en revue 782 articles en anglais sur les vaccins et la mortalité de l’enfant et nous avons constaté que seuls quelques-uns d’entre eux répondaient à des critères méthodologiques rigoureux. Si les données étudiées laissent entendre que le vaccin antirougeoleux entraîne bien la baisse de mortalité escomptée, il n’y a pas suffisamment de preuves pour envisager un effet dépassant celui obtenu par sa simple action contre la rougeole et ses séquelles. Notre examen de la littérature confirme la difficulté de ces questions et l’importance de la conception des études pour déterminer l’effet de chaque vaccin sur la mortalité globale.

Resumen
¿Tienen las vacunas infantiles efectos inespecíficos en la mortalidad?
En un reciente artículo de Kristensen et al. se sugería que la vacuna antisarampionosa y la vacuna BCG (bacilo de Calmette-Guérin) reducirían quizá la mortalidad más de lo que cabe esperar sólo de un efecto de protección contra el sarampión y la tuberculosis. En revisiones anteriores de los efectos potenciales de las vacunas infantiles sobre la mortalidad no se han considerado las características metodológicas de los estudios examinados. Las consideraciones metodológicas, sin embargo, tienen una función muy importante en las evaluaciones observacionales, en las que los factores de selección para la vacunación pueden ser difíciles de determinar. Tras examinar 782 artículos en inglés sobre las vacunas y la mortalidad en la niñez, sólo hallamos unos cuantos cuyo diseño satisficiera los criterios de rigor metodológico. Los datos examinados indican que la vacuna antisarampionosa reduce en efecto la mortalidad, pero no hay evidencia suficiente para afirmar que tenga un efecto adicional en la mortalidad aparte del relacionado con el sarampión y sus secuelas. Nuestra revisión de los datos extraídos de la bibliografía corrobora lo difícil que es intentar responder a esas consideraciones y la importancia del diseño de los estudios a la hora de determinar el efecto de determinadas vacunas en la mortalidad por todas las causas.

résumé

اللغة الإنجليزية حول اللافتات والمرضى لدى الأطفال. ووجدنا أن القليل من هذه المقالات كان صميمًا مواقيعاً معاييرًا منهجية صارمة. وتشير المصطلحات التي ستمارجعها إلى أن هناك بيانات غير قائمة للقراءة على مساحة في المراجعة تزيد لما تسمى الإحصاء بالنسبة بالحالة منعوقها. وتؤكد حقيقة مراجعتنا للمعطيات المتنوعة في الأدب الطبي على صعوبة الإجابة على هذه التساؤلات حول تأثيرات بعض اللافتات على معدل الوفيات العام.
References

### Table 1. Studies assessing mortality following measles infection among vaccinated and unvaccinated children

<table>
<thead>
<tr>
<th>Study Location</th>
<th>Study Type of vaccine</th>
<th>Age at vaccine (months)</th>
<th>Age at end of follow-up (months)</th>
<th>Complete ascertainment of mortality?</th>
<th>Adequate follow-up?</th>
<th>Consider socio-demographic?</th>
<th>Vacci-nated</th>
<th>Unvacci-nated</th>
<th>% of death of strong co-intervention?</th>
<th>% of children developing measles?</th>
<th>% of children among vaccinated</th>
<th>% of children among unvaccinated</th>
<th>Reduction in mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burstrom Kenya 1985–6</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>158</td>
<td>177</td>
<td>22.8 (36)</td>
<td>37.9 (67)</td>
<td>1.3 (2)</td>
<td>3.4 (6)</td>
</tr>
<tr>
<td>Burstrom Kenya 1987–8</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>310</td>
<td>167</td>
<td>13.5 (42)</td>
<td>35.9 (60)</td>
<td>0.6 (2)</td>
<td>4.2 (7)</td>
</tr>
<tr>
<td>Dollmon et al., 1989-91</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>14 299 py</td>
<td>22 760 py</td>
<td>1.1 (153)</td>
<td>3.6 (808)</td>
<td>0.1 (15)</td>
<td>0.6 (136)</td>
</tr>
</tbody>
</table>

* Numbers in parentheses are number of deaths.  
*b py = person-years.

### Table 2. Studies assessing the relationship between measles vaccine and childhood mortality

<table>
<thead>
<tr>
<th>Study Location</th>
<th>Type of study</th>
<th>Years of study</th>
<th>Age at vaccine (months)</th>
<th>Complete ascertainment of mortality?</th>
<th>Adequate follow-up?</th>
<th>Consider socio-demographic?</th>
<th>Vacci-nated</th>
<th>Unvacci-nated</th>
<th>% child deaths for cohort studies</th>
<th>No. of cases for case-control studies</th>
<th>Reduction in mortality (%)</th>
<th>Relative Absolute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kasongo PC a Zaire 1974–77</td>
<td>PC*</td>
<td>8–12</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>4.8 (14)</td>
<td>6.9 (24)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Koenig et al., 1990</td>
<td>CC, PC</td>
<td>1982–85</td>
<td>9–60</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2.4 (195)</td>
<td>4.2 (339)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>George et al., 1998</td>
<td>RC*</td>
<td>1986–91</td>
<td>6–12</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>1.1 (94)</td>
<td>3.2 (17)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Kumar et al., 2000</td>
<td>NCC*</td>
<td>1991–95</td>
<td>10</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Holt et al., 1990</td>
<td>PC, CC</td>
<td>1982–85</td>
<td>6–13</td>
<td>39</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>1.3 (3)</td>
<td>6.6 (73)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Adby et al., 1990</td>
<td>PC</td>
<td>1984–87</td>
<td>9</td>
<td>30</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Adby et al., 1996</td>
<td>RC</td>
<td>1989–91</td>
<td>9–10</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>4.3 (83)</td>
<td>6.7 (24)</td>
<td>–</td>
</tr>
<tr>
<td>Kristensen et al., 2000</td>
<td>PC</td>
<td>1995–96</td>
<td>9</td>
<td>13</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>1.8 (19)</td>
<td>4.0 (94)</td>
<td>–</td>
</tr>
<tr>
<td>Velema et al., 1991</td>
<td>NCC</td>
<td>1986–87</td>
<td>9–12</td>
<td>35</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>74</td>
</tr>
</tbody>
</table>

* PC = prospective cohort. 
*b Numbers in parentheses are number of deaths.  
*c Study is not a case–control study. 
*d NA = information not available in paper.  
*e CC = case–control. 
*f Numbers in parentheses are 95% confidence intervals.  
*g RC = retrospective cohort.  
*h NCC = nested case–control.  
*i Study is not a cohort study.